Navigation Links
Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
Date:9/2/2008

* -3.7* -3.8*

Week 24 mean -5.5* -5.2* -5.3*

Dysmenorrhea 2.4

Week 24 mean -1.5* -1.4* -1.7*

Responder Rate 86% 74% 86%

Non-Menstrual Pelvic

Pain 2.2

Week 24 mean -1.2* -1.2* -1.1*

Responder Rate 86% 77% 77%

VAS 78.7

Week 24 mean -31.8* -33.4* -35.5*

*ITT Analysis, p<0.0001

"We have treated over 600 subjects with elagolix in our extensive endometriosis clinical program, and have consistently seen a robust reduction in endometriosis pain using multiple outcome measures. In our previous Phase II studies we have shown rapid onset of action and sustained efficacy over three months. This study extends those findings, demonstrating significant and sustained pain reduction for six months," said Dr. O'Brien. "There is much more data to come from this study once patients complete the six month follow-up and the study is unblinded at an individual patient level. At that time we will be able to make correlations between pain scores, BMD, pharmacokinetic values, and hormonal levels on an individual patient basis, and we look forward to also sharing those results, as soon as they are available."

Treatment with elagolix was also safe and generally well tolerated. Discontinuation from the clinical trial due to adverse events (AE) was more common among women randomized to DMPA (16%) than those receiving elagolix 150 mg once daily (5%) or 75 mg twice daily (7%). This increased discontinuation in women randomized to DMPA was primarily attributable to irregular vaginal bleeding. The overall rate of AE reporting was comparable across all groups. The most common AE was headache;
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
10. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ) ... America (London, UK - November 16-18, 2015)" conference to their offering. ... America including Columbia, Peru , ... , Uruguay , Paraguay , ... America , Chile This seminar ...
(Date:9/2/2015)... , Sept. 2, 2015 Research ... addition of the "Medical Device Studies: Clinical ... conference to their offering. This ... are involved in gathering clinical evidence required for ... is required for all medical devices and the ...
(Date:9/2/2015)... DUBLIN , Sept. 2, 2015 ... the addition of Jain PharmaBiotech,s new report ... Technologies, Markets and Companies" to their offering. ... cell biology of the BBB have opened new ... the CNS. Several carrier or transport systems, enzymes, ...
Breaking Medicine Technology:Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2Medical Device Studies: Clinical Evidence Course - London, UK - November 10-11, 2015 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3
... , CHICAGO, Oct. 12 Ethicon Endo-Surgery today announced ... delivers system wide compression in a novel way through ... be fully operated with one hand. The one-handed design ... Endopath® products with the addition of a wider jaw ...
... , MAARSSEN, Netherlands, Oct. 12 Held in the ... South America and P-MEC South America pharma ingredients and production ... , At just over 4,900, visitor numbers for the 150+ ... of the 2008 launch event in Rio, with a major ...
Cached Medicine Technology:Ethicon Endo-Surgery Launches New Echelon Flex(TM) Endopath(R) Stapler That Delivers Echelon(TM) Compression, Now With Natural Articulation 2Ethicon Endo-Surgery Launches New Echelon Flex(TM) Endopath(R) Stapler That Delivers Echelon(TM) Compression, Now With Natural Articulation 3Sao Paulo Hosts Strong Second Year for South American Pharma Events 2
(Date:9/3/2015)... ... September 03, 2015 , ... According to an Oncology Nurse Advisor ... may help patients with oropharyngeal cancer (oral cancer) to be successfully diagnosed and treated ... caused by HPV infections, which have a high rate of success in treatment and ...
(Date:9/3/2015)... ... September 03, 2015 , ... Atlantic ... virtual conference, “Proven Pharmacy Benefit Strategies for a Rapidly Changing Marketplace.” In this ... Scripts and Milliman, will discuss how plan sponsors are adopting bold, innovative strategies ...
(Date:9/3/2015)... ... September 03, 2015 , ... ... efficacy endpoint data collection, cloud analytics and workflow solutions today announced the ... Lisbon, Portugal, September 22-24, 2015. The esteemed faculty of worldwide pharmaceutical and ...
(Date:9/3/2015)... ... 03, 2015 , ... A scar is an unavoidable result of incision or injury to the ... ability to heal itself. The appearance of a scar is dependent on many factors – ... skin pigmentation. ”Many scars fade to near invisibility on their own over a period of ...
(Date:9/3/2015)... ... September 03, 2015 , ... Mum n Me is pleased to announce the ... extra-large size that gives maximum protection from sun exposure, wind, bugs, and germs. The ... deliver non-slip assurance by keeping the cover securely in place. The new car seat ...
Breaking Medicine News(10 mins):Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3Health News:Speakers for Upcoming AIS Virtual Conference on Pharmacy Benefit Strategies Include Executives from CVS Health, Express Scripts 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 2Health News:ERT Announces Final Agenda, Faculty for European PRO / eCOA Congress 3Health News:Do I Have To Live With That Scar? 2Health News:Do I Have To Live With That Scar? 3Health News:Do I Have To Live With That Scar? 4Health News:Mum n Me Announces New Baby Car Seat Cover 2
... swings while walking could be an early sign of ... may help physicians apply treatments to slow further brain ... available. Parkinson,s disease is an age-related disorder involving ... by impaired movement and slow speech. "The ...
... ... communications technologies before, during and after crises , ... Washington, DC and London, UK (Vocus) December 10, ... publication today, Human Rights Day, on the use of communications technologies in humanitarian crises. ...
... 10 Centene Corporation (NYSE: CNC ) today ... at approximately 6:00 AM (Eastern Time) on Friday, January 8, ... AM (Eastern Time) to discuss the details of its guidance. ... N. Scheffel, Executive Vice President, Chief Financial Officer and Treasurer, ...
... , , , PARK CITY, Utah, Dec. 10 ... the fiscal 2009 fourth quarter and year ended September 30, 2009. ... million compared to $40.9 million for the same quarter of fiscal ... was $3.2 million, or $0.29 diluted earnings per share, compared to ...
... ... of a brand new loyalty scheme for Private Podiatrist Customers – Arthurs Club . ... (PRWEB) December 10, 2009 -- Algeos is ... Arthurs Club ., , , , ,Algeos has developed this ‘new to the UK’ loyalty ...
... of medications prescribed during a hospital visit, 44% of patients ... 96% were unable to recall the name of at least ... These findings are published today in the Journal of ... patient safety issue, with one review finding some degree of ...
Cached Medicine News:Health News:Irregular arm swing may point to Parkinson's disease 2Health News:New Report Examines the Role of Communications Technologies in Humanitarian Crises, 2Health News:New Report Examines the Role of Communications Technologies in Humanitarian Crises, 3Health News:New Report Examines the Role of Communications Technologies in Humanitarian Crises, 4Health News:Centene Corporation to Provide 2010 Financial Guidance On January 8, 2010 2Health News:Centene Corporation to Provide 2010 Financial Guidance On January 8, 2010 3Health News:Nutraceutical Reports Fiscal 2009 Year End Results 2Health News:Nutraceutical Reports Fiscal 2009 Year End Results 3Health News:Nutraceutical Reports Fiscal 2009 Year End Results 4Health News:Nutraceutical Reports Fiscal 2009 Year End Results 5Health News:Nutraceutical Reports Fiscal 2009 Year End Results 6Health News:Nutraceutical Reports Fiscal 2009 Year End Results 7Health News:Nutraceutical Reports Fiscal 2009 Year End Results 8Health News:Study highlights lack of patient knowledge regarding hospital medications 2
... to do the exams you want: ,Four probe ... the easiest water path probe in the industry, ... exactly what you need to. From full ... chamber, the P60 provides the clarity of images ...
... will find the samaritan AED easy ... medical and rescue professionals) will appreciate ... manual override, and the ECG monitoring ... AED is an exceptionally well-engineered, lightweight ...
... extraordinary combination of features make the ... multi-specialty clinical environment. The versatility and ... hardware allows you to perform a ... high-quality results., ,The ideal choice for ...
Assay for Anti-HTLV-I and Anti-HTLV-II...
Medicine Products: